<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997968</url>
  </required_header>
  <id_info>
    <org_study_id>CYT-0851-01</org_study_id>
    <nct_id>NCT03997968</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyteir Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyteir Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase
      1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics
      (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell
      malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for
      evaluation in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overexpression of activation-induced cytidine deaminase (AID) or other cytidine deaminases
      causes high rates of deoxyribonucleic acid (DNA) damage (mutations, double strand DNA breaks,
      and chromosome rearrangements) in a high number of patients with B-cell malignancies, such as
      NHL, MM, and CLL, and in a subset of patients with solid tumors, such as non-small cell lung
      cancer (NSCLC), sarcoma, breast cancer, ovarian cancer, and squamous cell carcinoma of the
      head and neck. Cancer cells that overexpress AID and other cytidine deaminases rely on RAD51,
      a protein involved in homologous recombination, to repair the DNA damage caused by cytidine
      deaminases. Inhibition of RAD51 with CYT-0851 in preclinical models induces cell death, tumor
      growth delay or tumor regression.

      The Phase 1 part of the study will follow an accelerated titration design, which includes
      enrollment of single patient cohorts until certain criteria are met, followed by a standard
      3+3 design. This design will allow for identification of a recommended phase 2 dose (RP2D)
      level while dosing the least number of patients as possible at potentially sub-therapeutic
      doses. In the Phase 2 part of the study, preliminary efficacy will be evaluated in 6
      expansion cohorts (total n = 60-136), using a Simon two-stage design. The RP2D will be
      selected based on the MTD, the safety profile, PK, and available pharmacodynamics data
      generated from all subjects in Phase 1.

      In both Phase 1 and Phase 2, patients will be treated in continuous 28-day cycles and all
      patients will be assessed for response every 2 cycles. Treatment will be terminated if the
      patient progresses, cannot tolerate treatment, or withdraws consent from active therapy.
      Patients will undergo a safety evaluation approximately 1 month (28-35 days) after the last
      dose. Patients will be followed for response until progression is documented.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting Toxicity</measure>
    <time_frame>Phase 1: 12 months;</time_frame>
    <description>Identify nature and frequency of dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 Months</time_frame>
    <description>Percent of Patients responding to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the safety of CYT-0851
Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood CYT-0851 concentrations</measure>
    <time_frame>Phase 1: 12 months</time_frame>
    <description>Measure CYT-0851 concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>For responders, time from response to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from treatment start to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from treatment start to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory and ECG abnormalities</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of grade of laboratory and ECG abnormalities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Malignancy</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>DLBCL</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>CLL</condition>
  <arm_group>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label study. All patients will receive single agent CYT-0851 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT-0851</intervention_name>
    <description>All patients will receive CYT-0851 as a single agent</description>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Phase 1 Inclusion Criteria

          1. ECOG Performance Status of 0-1

          2. Measurable disease

          3. Willing to undergo a tumor biopsy

          4. Histologically-proven B cell malignancies, meeting the following criteria:

               1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy

               2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy

               3. Relapsed or progressive multiple myeloma on or after treatment

          5. Histologically-proven solid tumor meeting the following criteria:

               1. Metastatic breast cancer

               2. Recurrent squamous cell carcinoma of the head and neck

               3. Ovarian cancer

               4. Soft tissue sarcoma

               5. Recurrent metastatic or locally advanced pancreatic cancer

        Key Phase 2 Inclusion Criteria

          1. ECOG Performance Status of 0-1

          2. Measurable disease defined by disease-specific response criteria

          3. Site of disease amenable to a biopsy and willing to undergo a biopsy

          4. Biomarker positive on recent biopsy or bone marrow sample

          5. Histologically-proven B cell malignancies, meeting the following criteria: DLBCL, MCL,
             or Multiple Myeloma requiring therapy

          6. Histologically-proven solid tumors: Triple Negative Breast Cancer, Ovarian Cancer or
             biomarker positive cancers

        Key Exclusion Criteria

          1. Known history of brain metastases, unless treated (Phase 1 only) .

          2. Known history of meningeal involvement or meningeal carcinomatosis

          3. Spinal cord compression not definitively treated with surgery and/or radiation

          4. Laboratory assessments

               1. ANC &lt; 1.0 x 10^9/L; PLT &lt; 75 x 10^9/L; Hgb &lt; 9.0 g/dL

               2. Calculated Creatinine clearance (Cockcroft-Gault) &lt; 60 mL/min

               3. Hepatic function: AST &gt; 2.0 x ULN; ALT &gt; 2.0 x ULN; Total bilirubin &gt; 1.5 ;
                  Albumin &lt; 2.8 g/dL

          5. Screening QTc interval &gt; 450 milliseconds (males) and &gt; 470 ms for females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Renschler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cyteir Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Renschler, MD</last_name>
    <phone>(857) 285-4142</phone>
    <email>clinicaltrials@cyteir.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Doleman</last_name>
    <phone>857 322 4152</phone>
    <email>clinicaloperations@cyteir.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>720-754-2610</phone>
      <email>Susan.Hall3@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Shiraj Sen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolyn Simpson, RN</last_name>
      <phone>941-377-9993</phone>
      <email>KaSimpson@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manesh R Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at HUMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>chelsea.mccabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Stone</last_name>
      <phone>215-955-6407</phone>
      <email>Dennis.Stone@Jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Palmisiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davinia McComb, RN, OCN</last_name>
      <phone>615-815-9963</phone>
    </contact>
    <investigator>
      <last_name>Johanna C Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Travasos</last_name>
      <phone>713-563-4431</phone>
      <email>sktravasos@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Timothy A Yap, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harini Ramachandran</last_name>
      <phone>206-606-6448</phone>
      <email>harinir@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jacklin</last_name>
      <phone>414-804-8839</phone>
      <email>mjacklin@mcw.com</email>
    </contact>
    <investigator>
      <last_name>Mehdi Hamadani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, RÃ¼ter J, Mills KD. Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med. 2013 May 6;210(5):1021-33.</citation>
    <PMID>23589568</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral RAD51-inhibitor; refractory; B-cell; solid tumor</keyword>
  <keyword>DNA Damage Repair inhibitor</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

